A PHASE IIA STUDY OF SINGLE-AGENT MOR208, AN FC-OPTIMIZED ANTI-CD19 ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA
Author(s): ,
Wojciech Jurczak
Affiliations:
Jagiellonian University,Kraków,Poland
,
Pier Luigi Zinzani
Affiliations:
University of Bologna,Bologna,Italy
,
Andre Goy
Affiliations:
John Theurer Cancer Center, Hackensack University Medical Center,Hackensack,United States
,
Mariano Provencio
Affiliations:
University Hospital Puerta De Hierro,Madrid,Spain
,
Zsolt Nagy
Affiliations:
Semmelweis University,Budapest,Hungary
,
Tadeusz Robak
Affiliations:
Medical University of Lodz,Lodz,Poland
,
Kami Maddocks
Affiliations:
The Ohio State University Comprehensive Cancer Center,Columbus,United States
,
Christian Buske
Affiliations:
University of Ulm,Ulm,Germany
,
Roman Korolkiewicz
Affiliations:
MorphoSys AG,Martinsried,Germany
,
Mark Winderlich
Affiliations:
MorphoSys AG,Martinsried,Germany
Kristie Blum
Affiliations:
The Ohio State University Comprehensive Cancer Center,Columbus,United States
EHA Learning Center. Jurczak W. Jun 12, 2015; 100254
Disclosure(s): Jagiellonian University
Dpt of Haematology
Prof. Dr. Wojciech Jurczak
Prof. Dr. Wojciech Jurczak

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)
Abstract: E990

Type: Eposter Presentation

Background
A number of second-generation monoclonal antibodies (mAbs) that target the antigens CD20 and CD19 have been evaluated across a range of non-Hodgkin's lymphoma (NHL) subtypes combined with chemotherapy, as a single agent, or as maintenance therapy. Although these agents are usually well tolerated and have demonstrated clinical activity in patients (pts) with NHL, there remains a high unmet medical need for new therapies for pts with relapsed or refractory (R-R) B-cell NHL. MOR208 is an Fc-engineered, humanized mAb that targets the B-cell-specific antigen CD19 and which possesses significantly enhanced antibody-dependent cell-mediated toxicity, a key mechanism for tumor cell killing. 

Aims
To evaluate the preliminary efficacy and safety of MOR208 in adult pts with relapsed or refractory NHL.

Methods
This is a non-randomized, open-label, multicenter, two-stage, phase IIa study of MOR208 in pts with R-R NHL previously treated with rituximab who were not candidates for high-dose chemotherapy with stem cell support. Adult pts with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), or other indolent NHL (iNHL), were treated with single-agent MOR208, at an intravenous dose of 12 mg/kg, weekly, over two 28-day cycles. Pts with at least stable disease according to the 2007 International Response Criteria were to continue treatment with MOR208 for another cycle. Pts achieving a complete or partial response (CR or PR) could then receive maintenance MOR208 every two or four weeks, depending on the investigator’s decision, until progression. Overall response rate (ORR = CR + PR) was the primary endpoint.

Results

By 17 November 2014, all pts (N = 89) had been enrolled (DLBCL, n = 35; FL, n = 31; MCL, n = 12; iNHL, n = 11); median age was 67 (range 35–90) years. Of these pts, 88% had stage III–IV disease and the median number of prior therapies was 2 (range 1–4). The mean number of cycles completed was 2.2 (0–3). The investigator-assessed responses across all NHL subtypes are shown in Table 1; the highest ORR was recorded in the DLBCL cohort (26%). Preliminary median duration of response was 7.7 months in the DLBCL group and 2.6 months in the FL group. Grade ≥3 non-hematologic treatment-emergent adverse events (TEAEs) were recorded in 30 pts (34%); disease progression, reported in 10 pts (11%), was most common. Grade ≥3 hematologic TEAEs were recorded in 8 pts (9%); neutropenia, reported in 5 pts (6%), was most common. Infusion-related reactions, reported in 8 pts (9%), were all grade 1–2 except for one case of dyspnea, which was grade 4. There were no treatment-related deaths.

Summary
MOR208 demonstrated encouraging single-agent efficacy with CRs observed in pts with R-R DLBCL, FL, and iNHL. MOR208 is well tolerated without significant infusional toxicity. Protocols are being developed to investigate MOR208 in combination with other agents.

Keyword(s): B cell lymphoma, CD19, Non-Hodgkin's lymphoma, Relapsed lymphoma

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings